Lipodystrophy in HIV Questions & Answers

1. Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019 Sep. 18 (9):829-840. [QxMD MEDLINE Link].

2. Huang JS, Lee D, Becerra K, Santos R, Barber E, Mathews WC. Body image in men with HIV. AIDS Patient Care STDS. 2006 Oct. 20(10):668-77. [QxMD MEDLINE Link].

3. Reynolds NR, Neidig JL, Wu AW, Gifford AL, Holmes WC. Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution. AIDS Care. 2006 Oct. 18(7):663-73. [QxMD MEDLINE Link].

4. Siqueira LR, Cunha GHD, Galvão MTG, Fontenele MSM, Fechine FV, Medeiros MS, et al. Effect of lipodystrophy on self-esteem and adherence to antiretroviral therapy in people living with HIV. AIDS Care. 2021 Jun 4. 1-10. [QxMD MEDLINE Link]. [Full Text].

5. Guzman N, Vijayan V. HIV-associated Lipodystrophy. StatPearls [Internet]. 2021 Jan. [QxMD MEDLINE Link]. [Full Text].

6. Soares FM, Costa IM. Treatment of HIV-associated facial lipoatrophy: impact on infection progression assessed by viral load and CD4 count. An Bras Dermatol. 2013 Jul-Aug. 88 (4):570-7. [QxMD MEDLINE Link]. [Full Text].

7. Milinkovic A, Martinez E. Current perspectives on HIV-associated lipodystrophy syndrome. J Antimicrob Chemother. 2005 Jul. 56 (1):6-9. [QxMD MEDLINE Link]. [Full Text].

8. Thet D, Siritientong T. Antiretroviral Therapy-Associated Metabolic Complications: Review of the Recent Studies. HIV AIDS (Auckl). 2020. 12:507-524. [QxMD MEDLINE Link]. [Full Text].

9. Clark WA, Cress EM. Nutritional Issues and Positive Living in Human Immunodeficiency Virus/AIDS. Nurs Clin North Am. 2018 Mar. 53 (1):13-24. [QxMD MEDLINE Link]. [Full Text].

10. Santiprabhob J, Chokephaibulkit K, Khantee P, Maleesatharn A, Phonrat B, Phongsamart W, et al. Adipocytokine dysregulation, abnormal glucose metabolism, and lipodystrophy in HIV-infected adolescents receiving protease inhibitors. Cytokine. 2020 Dec. 136:155145. [QxMD MEDLINE Link]. [Full Text].

11. Raggio GA, Looby SE, Robbins GK, Park ER, Sweek EW, Safren SA, et al. Psychosocial Correlates of Body Image and Lipodystrophy in Women Aging With HIV. J Assoc Nurses AIDS Care. 2020 Mar-Apr. 31 (2):157-166. [QxMD MEDLINE Link]. [Full Text].

12. Delannoy A, Poirier M, Bell B. Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies. Viruses. 2019 Mar 18. 11 (3):269. [QxMD MEDLINE Link]. [Full Text].

13. Steens JM, Scherrer D, Gineste P, Barrett PN, Khuanchai S, Winai R, et al. Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study. Antimicrob Agents Chemother. 2017 Jul. 61 (7):e00545-17. [QxMD MEDLINE Link]. [Full Text].

14. Bogner JR, Vielhauer V, Beckmann RA, Michl G, Wille L, Salzberger B, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001 Jul 1. 27(3):237-44. [QxMD MEDLINE Link].

15. Bonnet E, Ruidavets JB, Tuech J, Ferrières J, Collet X, Fauvel J, et al. Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab. 2001 Jan. 86(1):296-302. [QxMD MEDLINE Link].

16. Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001 Feb 24. 357(9256):592-8. [QxMD MEDLINE Link].

17. Rakotoambinina B, Médioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr. 2001 Aug 15. 27(5):443-9. [QxMD MEDLINE Link].

18. van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001 May 4. 15(7):847-55. [QxMD MEDLINE Link].

19. Bonnet E, Genoux A, Bernard J, Fauvel J, Massip P, Perret B. Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy. Clin Chem Lab Med. 2007. 45(7):815-21. [QxMD MEDLINE Link].

20. Domingo P, Mateo MG, Pruvost A, Torres F, Salazar J, Gutierrez MD, et al. Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40:01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients. PLoS One. 2013. 8(6):e67035. [QxMD MEDLINE Link]. [Full Text].

21. de Souza Dantas Oliveira SH, de Souza Aarão TL, da Silva Barbosa L, Souza Lisbôa PG, Tavares Dutra CD, Margalho Sousa L, et al. Immunohistochemical analysis of the expression of TNF-alpha, TGF-beta, and caspase-3 in subcutaneous tissue of patients with HIV lipodystrophy syndrome. Microb Pathog. 2014 Feb-Mar. 67-68:41-7. [QxMD MEDLINE Link].

22. Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet. 2014 Jan. 59(1):16-23. [QxMD MEDLINE Link].

23. Klos B, Patel P, Rose C, Bush T, Conley L, Kojic EM, et al. Lower serum adiponectin level is associated with lipodystrophy among HIV-infected men in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN) study. HIV Med. 2019 Sep. 20 (8):534-541. [QxMD MEDLINE Link].

24. Dasuri K, Pepping JK, Fernandez-Kim SO, Gupta S, Keller JN, Scherer PE, et al. Elevated adiponectin prevents HIV protease inhibitor toxicity and preserves cerebrovascular homeostasis in mice. Biochim Biophys Acta. 2016 Jun. 1862 (6):1228-35. [QxMD MEDLINE Link].

25. Akita S, Suzuki K, Yoshimoto H, Ohtsuru A, Hirano A, Yamashita S. Cellular Mechanism Underlying Highly-Active or Antiretroviral Therapy-Induced Lipodystrophy: Atazanavir, a Protease Inhibitor, Compromises Adipogenic Conversion of Adipose-Derived Stem/Progenitor Cells through Accelerating ER Stress-Mediated Cell Death in Differentiating Adipocytes. Int J Mol Sci. 2021 Feb 20. 22 (4):2114. [QxMD MEDLINE Link]. [Full Text].

26. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007 Dec. 7(12):787-96. [QxMD MEDLINE Link].

27. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS. 1999 Nov 12. 13(16):2311-2. [QxMD MEDLINE Link].

28. Gentil C, Le Jan S, Philippe J, Leibowitch J, Sonigo P, Germain S, et al. Is oxygen a key factor in the lipodystrophy phenotype?. Lipids Health Dis. 2006 Oct 18. 5:27. [QxMD MEDLINE Link].

29. Arama V, Munteanu DI, Streinu Cercel A, Ion DA, Mihailescu R, Tiliscan C, et al. Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin. J Endocrinol Invest. 2014 Jun. 37(6):533-9. [QxMD MEDLINE Link].

30. Peraire J, López-Dupla M, Alba V, Beltrán-Debón R, Martinez E, Domingo P, et al. HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma. Clin Microbiol Infect. 2015 Jul. 21 (7):711.e1-8. [QxMD MEDLINE Link].

31. Domingo P, Lamarca MK, Gallego-Escuredo JM, Torres F, Domingo JC, Villarroya J, et al. Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients. J Antimicrob Chemother. 2015. 70 (6):1825-32. [QxMD MEDLINE Link].

32. Pastryk JE, Rusek M, Bełtowski J. Effects of antiretroviral treatment on paraoxonase 1 (PON1) activity in rats. Chem Biol Interact. 2016 Jul 1. [QxMD MEDLINE Link].

33. Brigante G, Diazzi C, Ansaloni A, et al. Gender differences in GH response to GHRH+ARG in lipodystrophic patients with HIV: a key role for body fat distribution. Eur J Endocrinol. 2014 May. 170(5):685-96. [QxMD MEDLINE Link].

34. Haugaard SB, Andersen O, Vølund A, Hansen BR, Iversen J, Andersen UB, et al. Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Clin Endocrinol (Oxf). 2005 Mar. 62(3):354-61. [QxMD MEDLINE Link].

35. Stankov MV, Lücke T, Das AM, Schmidt RE, Behrens GM. Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors. Antivir Ther. 2007. 12(2):205-16. [QxMD MEDLINE Link].

36. Cherry CL, Lal L, Thompson KA, McLean CA, Ross LL, Hernandez J, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr. 2005 Mar 1. 38(3):263-7. [QxMD MEDLINE Link].

37. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS. 1999 Apr 16. 13(6):735-7. [QxMD MEDLINE Link].

38. López-Dupla M, Maymó-Masip E, Martínez E, Domingo P, Leal M, Peraire J, et al. HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels. PLoS One. 2015. 10 (12):e0144789. [QxMD MEDLINE Link].

39. Sutinen J, Yki-Järvinen H. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab. 2007 Mar. 292(3):E687-92. [QxMD MEDLINE Link].

40. Lindegaard B, Hvid T, Wolsk Mygind H, Mortensen OH, Grøndal T, Abildgaard J, et al. Low expression of IL-18 and IL-18 receptor in human skeletal muscle is associated with systemic and intramuscular lipid metabolism-Role of HIV lipodystrophy. PLoS One. 2018. 13 (1):e0186755. [QxMD MEDLINE Link].

41. Dragović G, Dimitrijević B, Khawla AM, Soldatović I, Andjić M, Jevtović D, et al. Lower levels of IL-4 and IL-10 influence lipodystrophy in HIV/AIDS patients under antiretroviral therapy. Exp Mol Pathol. 2017 Apr. 102 (2):210-214. [QxMD MEDLINE Link].

42. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006 Oct 24. 20(16):2043-50. [QxMD MEDLINE Link].

43. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004 Apr 30. 18(7):1029-36. [QxMD MEDLINE Link].

44. Viganò A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, et al. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz. Antivir Ther. 2007. 12(3):297-302. [QxMD MEDLINE Link].

45. Schwenk A, Breuer JP, Kremer G, Römer K, Bethe U, Franzen C, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study. Eur J Med Res. 2000 Oct 30. 5(10):443-8. [QxMD MEDLINE Link].

46. Dieterich D. Incidence of body habitus changes in a cohort of 700 HIV-infected patients. Presented at: 36th Annual Meeting of Infectious Disease Society of America. November 12-15, 1998.

47. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000 Jul 10. 160(13):2050-6. [QxMD MEDLINE Link].

48. Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract. 2007 Jun. 61(6):999-1014. [QxMD MEDLINE Link].

49. Dong K, Flynn MM, Dickinson BP, et al. Changes in body habitus in HIV(+) women after initiation of protease inhibitor therapy. Presented at: 12th World AIDS Conference. 1998.

50. Elwood W. Lipodystrophy: cause for concern with protease inhibitor therapy?. Reactions. 1998. 713:3-4.

51. Alves MD, Brites C, Sprinz E. HIV-associated lipodystrophy: a review from a Brazilian perspective. Ther Clin Risk Manag. 2014. 10:559-66. [QxMD MEDLINE Link]. [Full Text].

52. Sorli Redó ML, Knobel Freud H, Montero M, Jericó Alba C, Guelar Grimberg A, Pedro-Botet Montoya J. [Sex influence in lipodystrophy of HIV-infected patients and its association with cardiovascular risk factors]. An Med Interna. 2007 Apr. 24(4):168-72. [QxMD MEDLINE Link].

53. Price J, Hoy J, Ridley E, Nyulasi I, Paul E, Woolley I. Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men. Sex Health. 2015 Jun. 12 (3):240-8. [QxMD MEDLINE Link].

54. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999 Jun 19. 353(9170):2093-9. [QxMD MEDLINE Link].

55. De Luca A, Murri R, Damiano F, Ammassari A, Antinori A. "Buffalo hump" in HIV-1 infection. Lancet. 1998 Jul 25. 352(9124):320. [QxMD MEDLINE Link].

56. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998 Mar 21. 351(9106):867-70. [QxMD MEDLINE Link].

57. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 1998 Jul. 27(1):65-7. [QxMD MEDLINE Link].

58. Palella FJ Jr, Chmiel JS, Riddler SA, Calhoun B, Dobs A, Visscher B, et al. A novel pattern of lipoaccumulation in HIV-infected men. JAMA. 2006 Aug 16. 296(7):766-8. [QxMD MEDLINE Link].

59. Guaraldi G, Orlando G, Squillace N, Roverato A, De Fazio D, Vandelli M, et al. Prevalence of and risk factors for pubic lipoma development in HIV-infected persons. J Acquir Immune Defic Syndr. 2007 May 1. 45(1):72-6. [QxMD MEDLINE Link].

60. Dank JP, Colven R. Protease inhibitor-associated angiolipomatosis. J Am Acad Dermatol. 2000 Jan. 42(1 Pt 1):129-31. [QxMD MEDLINE Link].

61. Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDS. 2001 Aug. 15(8):411-23. [QxMD MEDLINE Link].

62. Beraldo RA, Vassimon HS, Aragon DC, Navarro AM, Albuquerque de Paula FJ, Foss-Freitas MC. Proposed ratios and cutoffs for the assessment of lipodystrophy in HIV-seropositive individuals. Eur J Clin Nutr. 2014 Jul 30. [QxMD MEDLINE Link].

63. Gellett LR, Haddon L, Maskell GF. CT appearances of HIV-related lipodystrophy syndrome. Br J Radiol. 2001 Apr. 74(880):382-3. [QxMD MEDLINE Link].

64. Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS. 2001 May 25. 15(8):975-82. [QxMD MEDLINE Link].

65. Martínez E, García-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis. 2000 Nov. 31(5):1266-73. [QxMD MEDLINE Link].

66. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010 Mar 1. 53(3):311-22. [QxMD MEDLINE Link].

67. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007 Dec 6. 357(23):2359-70. [QxMD MEDLINE Link].

68. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 Sep. 95(9):4291-304. [QxMD MEDLINE Link].

69. Rodriguez AJ, Mastronardi CA, Paz-Filho GJ. New advances in the treatment of generalized lipodystrophy: role of metreleptin. Ther Clin Risk Manag. 2015. 11:1391-400. [QxMD MEDLINE Link].

70. Lightbourne M, Wolska A, Abel BS, Rother KI, Walter M, Kushchayeva Y, et al. Apolipoprotein CIII and Angiopoietin-like Protein 8 are Elevated in Lipodystrophy and Decrease after Metreleptin. J Endocr Soc. 2021 Feb 1. 5 (2):bvaa191. [QxMD MEDLINE Link]. [Full Text].

71. Liao J, Wilkinson A. Three Clinical Scenarios of Acquired Lipodystrophy. Proceedings of UCLA Health. 2021. 25:1-3. [Full Text].

72. Baldini F, Di Giambenedetto S, Cingolani A, Murri R, Ammassari A, De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS. 2000 Jul 28. 14(11):1660-2. [QxMD MEDLINE Link].

73. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA. 2000 Jul 26. 284(4):472-7. [QxMD MEDLINE Link].

74. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes. 1993 May. 42(5):696-705. [QxMD MEDLINE Link].

75. Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract. 1995 Aug. 28 Suppl:S185-94. [QxMD MEDLINE Link].

76. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2004 May 18. 140(10):786-94. [QxMD MEDLINE Link].

77. Cavalcanti RB, Raboud J, Shen S, et al. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis. 2007 Jun 15. 195(12):1754-61. [QxMD MEDLINE Link].

78. Raboud JM, Diong C, Carr A, et al. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials. 2010 Jan-Feb. 11(1):39-50. [QxMD MEDLINE Link].

79. Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis. 2010 Jun 23. 10:183. [QxMD MEDLINE Link]. [Full Text].

80. Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2001 Aug. 86(8):3480-7. [QxMD MEDLINE Link].

81. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS. 1999 Oct 22. 13(15):2099-103. [QxMD MEDLINE Link].

82. Patni N, Diaz EG, Cabral MD, Siqueira LM, Diaz A. Worsening hypertriglyceridemia with oral contraceptive pills in an adolescent with HIV-associated lipodystrophy: a case report and review of the literature. J Pediatr Endocrinol Metab. 2014 Nov 1. 27(11-12):1247-51. [QxMD MEDLINE Link].

83. Vallejo A, Garcia-Ruano AA, Pinilla C, Castellano M, Deleyto E, Perez-Cano R. Comparing Efficacy and Costs of Four Facial Fillers in Human Immunodeficiency Virus-Associated Lipodystrophy: A Clinical Trial. Plast Reconstr Surg. 2018 Mar. 141 (3):613-623. [QxMD MEDLINE Link].

84. Pai S, Mudgal J, Kamath BV, Pai KSR. An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein-short review. Pharmacol Rep. 2021 Apr 11. Online ahead of print:[QxMD MEDLINE Link]. [Full Text].

85. Scherrer D, Rouzier R, Noel Barrett P, Steens JM, Gineste P, Murphy RL, et al. Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects. J Antimicrob Chemother. 2017 Mar 1. 72 (3):820-828. [QxMD MEDLINE Link]. [Full Text].

86. Vautrin A, Manchon L, Garcel A, Campos N, Lapasset L, Laaref AM, et al. Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing. Sci Rep. 2019 Jan 28. 9 (1):792. [QxMD MEDLINE Link]. [Full Text].

87. Lu Y, Bohn-Wippert K, Pazerunas PJ, Moy JM, Singh H, Dar RD. Screening for gene expression fluctuations reveals latency-promoting agents of HIV. Proc Natl Acad Sci U S A. 2021 Mar 16. 118 (11):e2012191118. [QxMD MEDLINE Link]. [Full Text].

88. Mediouni S, Chinthalapudi K, Ekka MK, Usui I, Jablonski JA, Clementz MA, et al. Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat. mBio. 2019 Feb 5. 10 (1):e02662-18. [QxMD MEDLINE Link]. [Full Text].

89. Vansant G, Bruggemans A, Janssens J, Debyser Z. Block-And-Lock Strategies to Cure HIV Infection. Viruses. 2020 Jan 10. 12 (1):84. [QxMD MEDLINE Link]. [Full Text].

90. Rutsaert S, Steens JM, Gineste P, Cole B, Kint S, Barrett PN, et al. Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study. J Virus Erad. 2019 Jan 1. 5 (1):10-22. [QxMD MEDLINE Link]. [Full Text].

91. Nelson L, Stewart KJ. Plastic surgical options for HIV-associated lipodystrophy. J Plast Reconstr Aesthet Surg. 2008. 61(4):359-65. [QxMD MEDLINE Link].

92. Davison SP, Timpone J Jr, Hannan CM. Surgical algorithm for management of HIV lipodystrophy. Plast Reconstr Surg. 2007 Dec. 120(7):1843-58. [QxMD MEDLINE Link].

93. Rauso R, Rusciani A, Curinga G. An adipocitolitic aqueous micro-gelatinous solution for buffalo hump deformity reduction. J Drugs Dermatol. 2014 Oct. 13 (10):1282-4. [QxMD MEDLINE Link].

94. Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, Molina JM. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr. 2005 Apr 1. 38(4):393-8. [QxMD MEDLINE Link].

95. Quintas RC, de França ER, de Petribú KC, Ximenes RA, Quintas LF, Cavalcanti EL, et al. Treatment of facial lipoatrophy with polymethylmethacrylate among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): impact on the quality of life. Int J Dermatol. 2014 Apr. 53(4):497-502. [QxMD MEDLINE Link].

96. Blashill AJ, Goshe BM, Robbins GK, Mayer KH, Safren SA. Body image disturbance and health behaviors among sexual minority men living with HIV. Health Psychol. 2014 Jul. 33(7):677-80. [QxMD MEDLINE Link]. [Full Text].

97. Rauso R. 5-year study of a polyacrylamide hydrogel-based filler for rehabilitation of HIV-related facial lipoatrophy. Aesthet Surg J. 2015 Nov. 35 (8):1021-9. [QxMD MEDLINE Link].

98. Gooderham M, Solish N. Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy. Dermatol Surg. 2005 Jan. 31(1):104-8. [QxMD MEDLINE Link].

99. Ritt MJ, Hillebrand-Haverkort ME, ten Veen JH. Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy. Acta Chir Plast. 2001. 43(2):54-6. [QxMD MEDLINE Link].

100. Wildemore JK, Jones DH. Persistent granulomatous inflammatory response induced by injectable poly-L-lactic acid for HIV lipoatrophy. Dermatol Surg. 2006 Nov. 32(11):1407-9; discussion 1409. [QxMD MEDLINE Link].

101. Loonam CR, Mullen A. Nutrition and the HIV-associated lipodystrophy syndrome. Nutr Res Rev. 2012 Dec. 25(2):267-87. [QxMD MEDLINE Link].

102. Roubenoff R, Weiss L, McDermott A, Heflin T, Cloutier GJ, Wood M, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS. 1999 Jul 30. 13(11):1373-5. [QxMD MEDLINE Link].

103. Jaggers JR, Prasad VK, Dudgeon WD, Blair SN, Sui X, Burgess S, et al. Associations between physical activity and sedentary time on components of metabolic syndrome among adults with HIV. AIDS Care. 2014. 26(11):1387-92. [QxMD MEDLINE Link]. [Full Text].

David T Robles, MD, PhD, FAAD Dermatologist, Oak Tree Dermatology

David T Robles, MD, PhD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Jacquiline Habashy, DO, MSc Resident Physician, Department of Dermatology, Western University of Health Sciences College of Osteopathic Medicine of the Pacific

Jacquiline Habashy, DO, MSc is a member of the following medical societies: American Osteopathic College of Dermatology

Disclosure: Nothing to disclose.

Savannah Potter, BS Medical Scribe, Department of Dermatology, San Antonio Regional Hospital

Disclosure: Nothing to disclose.

David F Butler, MD Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Association of Military Dermatologists, Phi Beta Kappa, Texas Dermatological Society

Disclosure: Nothing to disclose.

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Roy M Colven, MD Associate Professor of Medicine (Dermatology), Adjunct Associate Professor of Global Health, University of Washington School of Medicine; Section Head of Dermatology, Harborview Medical Center

Roy M Colven, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American Telemedicine Association, Phi Beta Kappa, and Washington State Medical Association

Disclosure: Nothing to disclose.

Ali Hendi, MD Assistant Professor, Department of Dermatology, Mayo Clinic College of Medicine at Jacksonville; Consulting Staff, Mayo Clinic

Disclosure: Nothing to disclose.

Suzan Obagi, MD Assistant Professor, Department of Dermatology, University of Pittsburgh School of Medicine

Disclosure: Nothing to disclose.

Jonathan M Olson, MD Fellow, Division of Dermatology, University of Washington Medical Center

Jonathan M Olson, MD is a member of the following medical societies: American Medical Association

Disclosure: Nothing to disclose.

Jason Whalen, MD Dermatologist, University of Pittsburgh Medical Center

Disclosure: Nothing to disclose.

What would you like to print?

• Print this section
• Print the entire contents of
• Print the entire contents of article